Concentration effect relationship of CYP3A inhibition by ritonavir in humans

European Journal of Clinical Pharmacology

Volumn 69, Issue 10, 2013, Pages 1795-1800

  Eichbaum, Christine ^a   Cortese, Marianna ^a   Blank, Antje ^a   Burhenne, Jürgen ^a   Mikus, Gerd ^a  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

Author keywords

CYP3A; Inhibition; Midazolam; Ritonavir

Indexed keywords

CYTOCHROME P450 3A; MIDAZOLAM; MIDAZOLAM MALEATE; RITONAVIR;

ADULT; AREA UNDER THE CURVE; ARTICLE; CAUCASIAN; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CONCENTRATION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; HUMAN; IC 50; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; UNSPECIFIED SIDE EFFECT;

ADULT; AREA UNDER CURVE; CYTOCHROME P-450 CYP3A; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HIV PROTEASE INHIBITORS; HUMANS; MALE; MIDAZOLAM; MIDDLE AGED; NONTHERAPEUTIC HUMAN EXPERIMENTATION; RITONAVIR; YOUNG ADULT;

EID: 84884816288     PISSN: 00316970     EISSN: 14321041     Source Type: Journal    
DOI: 10.1007/s00228-013-1530-8     Document Type: Article

References (23)

1. Guengerich FP (2008) Cytochrome p450 and chemical toxicology. Chem Res Toxicol 21(1):70-83
2. Gass RJ, Gal J, Fogle PW, Detmar-Hanna D, Gerber JG (1998) Neither dapsone hydroxylation nor cortisol 6beta-hydroxylation detects the inhibition of CYP3A4 by HIV-1 protease inhibitors. Eur J Clin Pharmacol 54(9-10):741-747
3. Greenblatt DJ, von Moltke LL, Harmatz JS, Durol AL, Daily JP, Graf JA, Mertzanis P, Hoffman JL, Shader RI (2000) Differential impairment of triazolam and zolpidem clearance by ritonavir. J Acquir Immune Defic Syndr 24(2):129-136
4. Hsu A, Granneman GR, Bertz RJ (1998) Ritonavir. Clinical pharmacokinetics and interactions with other anti-HIV agents. Clin Pharmacokinet 35(4):275-291
5. Ouellet D, Hsu A, Qian J, Locke CS, Eason CJ, Cavanaugh JH, Leonard JM, Granneman GR (1998) Effect of ritonavir on the pharmacokinetics of ethinyl oestradiol in healthy female volunteers. Br J Clin Pharmacol 46(2):111-116
6. Zhou SF, Xue CC, Yu XQ, Li C, Wang G (2007) Clinically important drug interactions potentially involving mechanism-based inhibition of cytochrome P450 3A4 and the role of therapeutic drug monitoring. Ther Drug Monit 29(6):687-710
7. Katzenmaier S, Markert C, Mikus G (2010) Proposal of a new limited sampling strategy to predict CYP3A activity using a partial AUC of midazolam. Eur J Clin Pharmacol 66(11):1137-1141
8. Lee JI, Chaves-Gnecco D, Amico JA, Kroboth PD, Wilson JW, Frye RF (2002) Application of semisimultaneous midazolam administration for hepatic and intestinal cytochrome P450 3A phenotyping. Clin Pharmacol Ther 72(6):718-728
9. Lee LS, Bertino JS Jr, Nafziger AN (2006) Limited sampling models for oral midazolam: midazolam plasma concentrations, not the ratio of 1-hydroxymidazolam to midazolam plasma concentrations, accurately predicts AUC as a biomarker of CYP3A activity. J Clin Pharmacol 46(2):229-234
10. Katzenmaier S, Markert C, Riedel KD, Burhenne J, Haefeli WE, Mikus G (2011) Determining the time course of CYP3A inhibition by potent reversible and irreversible CYP3A inhibitors using A limited sampling strategy. Clin Pharmacol Ther 90(5):666-673
11. Knox TA, Oleson L, von Moltke LL, Kaufman RC, Wanke CA, Greenblatt DJ (2008) Ritonavir greatly impairs CYP3A activity in HIV infection with chronic viral hepatitis. J Acquir Immune Defic Syndr 49(4):358-368
12. Greenblatt DJ, Peters DE, Oleson LE, Harmatz JS, MacNab MW, Berkowitz N, Zinny MA, Court MH (2009) Inhibition of oral midazolam clearance by boosting doses of ritonavir, and by 4,4-dimethyl-benziso-(2H)-selenazine (ALT-2074), an experimental catalytic mimic of glutathione oxidase. Br J Clin Pharmacol 68(6):920-927
13. Mathias AA, West S, Hui J, Kearney BP (2009) Dose-response of ritonavir on hepatic CYP3A activity and elvitegravir oral exposure. Clin Pharmacol Ther 85(1):64-70
14. European Medicines Agency (2012) Norvir-EMEA/H/C/000127 -II/0115
15. Quintela O, Cruz A, Concheiro M, de Castro A, Lopez-Rivadulla M (2004) A sensitive, rapid and specific determination of midazolam in human plasma and saliva by liquid chromatography/electrospray mass spectrometry. Rapid Commun Mass Spectrom 18(24):2976-2982
16. Fuchs I, Hafner-Blumenstiel V, Markert C, Burhenne J, Weiss J, Haefeli WE, Mikus G (2012) Effect of the CYP3A inhibitor ketoconazole on the PXR-mediated induction of CYP3A activity. Eur J Clin Pharmacol 69(3):507-513
17. Hafner V, Jager M, Matthee AK, Ding R, Burhenne J, Haefeli WE, Mikus G (2010) Effect of simultaneous induction and inhibition of CYP3A by St John's Wort and ritonavir on CYP3A activity. Clin Pharmacol Ther 87(2):191-196
18. Hill A, van der Lugt J, Sawyer W, Boffito M (2009) How much ritonavir is needed to boost protease inhibitors? Systematic review of 17 dose-ranging pharmacokinetic trials. AIDS 23(17):2237-2245
19. Kumar GN, Rodrigues AD, Buko AM, Denissen JF (1996) Cytochrome P450-mediated metabolism of the HIV-1 protease inhibitor ritonavir (ABT-538) in human liver microsomes. J Pharmacol Exp Ther 277(1):423-431
20. Von Moltke LL, Durol AL, Duan SX, Greenblatt DJ (2000) Potent mechanism-based inhibition of human CYP3A in vitro by amprenavir and ritonavir: comparison with ketoconazole. Eur J Clin Pharmacol 56(3):259-261
21. Tran TH, Von Moltke LL, Venkatakrishnan K, Granda BW, Gibbs MA, Obach RS, Harmatz JS, Greenblatt DJ (2002) Microsomal protein concentration modifies the apparent inhibitory potency of CYP3A inhibitors. Drug Metab Dispos 30(12):1441-1445
22. Mikus G, Walter-Sack I (2013) CYP3A auto-inhibition of drug metabolism, an unrecognised mechanism of non-linearity in pharmacokinetics. Eur J Clin Pharmacol submitted
23. Culm-Merdek KE, von Moltke LL, Gan L, Horan KA, Reynolds R, Harmatz JS, Court MH, Greenblatt DJ (2006) Effect of extended exposure to grapefruit juice on cytochrome P450 3A activity in humans: comparison with ritonavir. Clin Pharmacol Ther 79(3):243-254